Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.102x

Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scope Fluidics SA balance sheet liabilities for a breakdown of total debt and financial obligations.

Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Tethys Petroleum Ltd
V:TPL
0.069x
CVC Income & Growth Limited
LSE:CVCE
0.023x
BTCS Inc
NASDAQ:BTCS
-0.011x
Ayes Celik Hasir ve Cit Sanayi AS
IS:AYES
-0.018x
Piscines Desjoyaux SA
PA:ALPDX
0.136x
Prime Securities Limited
NSE:PRIMESECU
-0.056x
Rapid Micro Biosystems Inc
NASDAQ:RPID
-0.071x
09women Co. Ltd.
KQ:366030
0.036x

Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)

The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SCP company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł146.35 Million
≈ $40.28 Million
zł-25.10 Million
≈ $-6.91 Million
-0.172x +27.15%
2023-12-31 zł80.93 Million
≈ $22.27 Million
zł-19.06 Million
≈ $-5.24 Million
-0.235x -178.45%
2022-12-31 zł332.97 Million
≈ $91.64 Million
zł-28.16 Million
≈ $-7.75 Million
-0.085x +94.44%
2021-12-31 zł14.58 Million
≈ $4.01 Million
zł-22.19 Million
≈ $-6.11 Million
-1.522x -215.52%
2020-12-31 zł33.09 Million
≈ $9.11 Million
zł-15.96 Million
≈ $-4.39 Million
-0.482x +6.93%
2019-12-31 zł20.22 Million
≈ $5.56 Million
zł-10.48 Million
≈ $-2.88 Million
-0.518x -23.38%
2018-12-31 zł12.81 Million
≈ $3.52 Million
zł-5.38 Million
≈ $-1.48 Million
-0.420x -43.76%
2017-12-31 zł16.88 Million
≈ $4.64 Million
zł-4.93 Million
≈ $-1.36 Million
-0.292x +57.84%
2016-12-31 zł5.58 Million
≈ $1.53 Million
zł-3.87 Million
≈ $-1.06 Million
-0.693x -966.74%
2015-12-31 zł6.70 Million
≈ $1.84 Million
zł535.69K
≈ $147.43K
0.080x --

About Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$103.68 Million
zł376.72 Million PLN
Market Cap Rank
#19045 Global
#151 in Poland
Share Price
zł138.20
Change (1 day)
-0.58%
52-Week Range
zł136.20 - zł180.80
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.